Related Experiment Video
Updated: Feb 20, 2026
13:45
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
13.3K
LTB4 and BLT1 in inflammatory arthritis
Yoshishige Miyabe1, Chie Miyabe1, Andrew D Luster1
1Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Seminars in Immunology
|October 19, 2017
Summary
Leukotriene B4 (LTB4) drives inflammatory arthritis by initiating and sustaining joint inflammation. Targeting the LTB4-BLT1 pathway offers a novel therapeutic strategy for rheumatoid arthritis and other inflammatory diseases.
Area of Science:
- Immunology
- Rheumatology
- Biochemistry
Background:
- Rheumatoid arthritis (RA) involves joint inflammation, with current treatments like TNF-α and IL-6 inhibitors showing limitations.
- Some RA patients are refractory to existing therapies, and broad immunosuppression increases infection risk.
- The leukotriene B4 (LTB4)-BLT1 pathway is implicated in RA pathogenesis, with elevated LTB4 levels observed in patients.
Purpose of the Study:
- To investigate the role of LTB4 as a key mediator in inflammatory arthritis.
- To explore novel therapeutic strategies targeting the LTB4-BLT1 pathway for RA treatment.
Main Methods:
- Analysis of LTB4 levels in patient samples (serum, synovial fluid, tissue).
- Mechanistic studies elucidating LTB4's role in inflammatory cascades.
- Evaluation of LTB4-BLT1 pathway blockade in preclinical models of arthritis.
Main Results:
- LTB4 is identified as a critical mediator in a cascade initiating and sustaining neutrophilic inflammation in arthritis.
- Elevated LTB4 levels are confirmed in RA patients compared to controls.
- Preclinical data support the potential of targeting the LTB4-BLT1 pathway.
Conclusions:
- The LTB4-BLT1 pathway is a significant driver of inflammatory arthritis pathogenesis.
- Targeting LTB4 offers a promising, potentially safer, therapeutic avenue for RA and related inflammatory conditions.
Related Concept Videos
01:24T Cell Types and Functions
2.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K
01:20The JAK-STAT Signaling Pathway
13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
01:29Inflammatory Bowel Disease IV: Pharmacological Management
828
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
828
01:28Inflammatory Response
17.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.3K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K